generalised convulsive status epilepticus
Neurology · 2022–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| midazolam Treatment of generalised convulsive status epilepticus (GCSE) in patients aged over 6 months. | Nov 2023 | Recommended with restriction | 18 individuals Epilepsy Australia · SCN2A Australia · Epilepsy Action Australia · Epilepsy Society of Australia and the National Paediatric Medicines |
| midazolam maleate Treatment of generalised convulsive status epilepticus (GCSE) in patients with epilepsy aged over 6 months and a high risk of status epilepticus. | Jul 2022 | Not recommended | input received Epilepsy Australia · Epilepsy Action Australia |
| midazolam Treatment of generalised convulsive status epilepticus (GCSE) in patients with epilepsy aged over 6 months and at high risk of status epilepticus. | Nov 2022 | Deferred | input received Epilepsy Australia · Epilepsy Action Australia |
Who spoke
Epilepsy Australia · Epilepsy Action Australia · SCN2A Australia · Epilepsy Society of Australia and the National Paediatric Medicines
What the PBS pays
$2M in government benefit over 2024–25, across 17,162 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| midazolam | $1.1M |
| midazolam maleate | $1.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.